Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

UK Biotechnology Firm Receives £700k Funding Boost

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
Investment will progress the development of a new generation of biological therapeutics through advanced glycosylation technologies.

Glythera Ltd is delighted to announce that it has successfully achieved a number of technical and commercial milestones which has resulted in the release of a second tranche of funding totalling £700k from IP Group and its managed fund, the Finance for Business North East Technology Fund.

Glythera, a UK based spin out specialising in a new generation of biological therapeutics through advanced glycosylation technologies, received an initial investment of £600,000 in April 2012.The funds have been used by the company to continue the development of a new generation of biological therapeutics including its core technologies - Permalink™ and Permacarb™. These technologies will be used to create drugs with unprecedented biological stability, bioavailability and therapeutic efficacy.

Glythera reached its technical and commercial targets ahead of schedule including the validation of Glythera’s Permalink™ technology and establishment of partnerships with four pharmaceutical companies. This demonstrates how the company is effectively managing the financial investment it has received. The third tranche of investment will be made available once further technological progress has been made and commercial traction successfully achieved.

Glythera is based in the Newcastle-upon-Tyne INEX incubator facility, ideally placed within the North East of England which is fast becoming one of the top ten places in the world to do science based business. With the financial support from IP Group, Glythera is continuing to establish itself within the region and has demonstrated its commitment to growth with the creation of seven new jobs.

The additional investment coincides with Glythera consolidating its board of directors with the addition of Cassie Doherty from IP Group. With a wealth of expertise and experience in commercial development Cassie’s appointment represents a significant benefit to the company in achieving specific business development related outcomes. Cassie completes a team of three that comprises the board of directors at Glythera including CEO of Cyprotex and Chairman of Equinox Pharma Dr Anthony  Baxter and William Bains representing Bath University.

Commenting on the investment Dr Baxter said, “Glythera is a shining example of how a spin out company can be successfully brought to commercialisation. By meeting the criteria to receive the second installment of funding it has shown that it is capable of developing innovative technology in a challenging market. I am extremely pleased to be involved at this exciting time for the company and I look forward to continuing to working with the team as it leads the way in the development of ground breaking biological therapeutics for the benefit of the pharmaceutical industry.”

Chief Operating Officer Dr. David Simpson said, “We are delighted with the progress that has been made throughout the research and development process so far thanks to the expertise of the Glythera team in the discovery, development and manufacturing of complex biologics. This funding will enable us to continue with the commercialisation of our products and maximise the opportunities available to us in the market.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos